問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蘇勇曄

Recruiting

List

31Cases

2024-03-13 - 2028-03-13

Phase I

Active
A Phase I Open-label Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LXP1788 Injection in Patients with Advanced Solid Tumors.

  • Condition/Disease

    Solid Tumor Malignancies, Cancer

  • Test Drug

    注射劑

Participate Sites
2Sites

Recruiting2Sites

2024-12-01 - 2031-05-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-11-13 - 2026-12-31

Phase I

Active
A Phase I Study to Evaluate the Safety and Efficacy of RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer

  • Condition/Disease

    Pancreatic Cancer

  • Test Drug

    凍晶注射劑

Participate Sites
2Sites

Recruiting2Sites

2022-06-16 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-12-01 - 2022-12-31

Phase II

Completed
A Study of Nivolumab Combination Gemcitabine and S1 as the First-Line Treatment in Patients With Advanced Biliary Tract Cancer

  • Condition/Disease

    Advanced Biliary Tract Cancer

  • Test Drug

    OPDIVO

Participate Sites
7Sites

Recruiting7Sites

2020-09-01 - 2026-12-31

Phase II

Active
A Multicenter, Open-label, Single-arm, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 and Are Continuing ONO-4538 Treatment

  • Condition/Disease

    Pan-Tumor

  • Test Drug

    ONO-4538 (Nivolumab)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting3Sites

Terminated3Sites

2023-11-01 - 2027-12-31

Phase II

Active
An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients Not Previously Treated for Metastatic Pancreatic Adenocarcinoma

  • Condition/Disease

    Pancreatic Cancer

  • Test Drug

    注射液 凍晶注射劑

Participate Sites
5Sites

Recruiting5Sites

2021-10-01 - 2027-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting13Sites

Terminated3Sites

2021-01-01 - 2026-12-31

Phase I

Active
A Phase 1 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

  • Condition/Disease

    Cholangiocarcinoma

  • Test Drug

    膠囊劑 錠劑

Participate Sites
2Sites

Recruiting2Sites

2023-08-10 - 2026-12-31

Phase I

Active
A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    MK-1084 Gisuda Injection

Participate Sites
3Sites

Recruiting3Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB